drugset / Trial / NCT05885854

XTR003 PET Radiotracer for the Detection of Viable Myocardium

NCT05885854

Phase 2 Completed 51 enrolled Sinotau Pharmaceutical Group
NaSingle-groupOpen-labelDiagnostic

Summary

The study was designed to explore the clinical feasibility of XTR003, a PET myocardial fatty-acid tracer, for the detection of viable myocardium in patients with ischemic heart disease (IHD).

Timeline

Start
2021-12-15
Primary completion
2023-03-04
Completion
2023-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject XTR003 Diagnostic / imaging agent 222 mbq Intravenous
Subject XTR003 Diagnostic / imaging agent 296 mbq Intravenous
Background 18F-FDG Diagnostic / imaging agent 74 mbq Intravenous
Background 18F-FDG Diagnostic / imaging agent 111 mbq Intravenous

Indications